Borosil Scientific Reports Q2 Revenue of ₹1.15 Billion Versus ₹1.1 Billion YoY

Market snapshot: Borosil Scientific Limited reported top-line expansion in its Q2 financial results, generating revenue of ₹1.15 billion (₹115 crore) compared to ₹1.10 billion (₹110 crore) in the corresponding quarter of the previous fiscal year.

Data Snapshot

• Q2 Revenue: ₹1.15 billion (₹115 crore)
• Prior Year Q2 Revenue: ₹1.10 billion (₹110 crore)
• YoY Growth Rate: ≈4.55% YoY (derived: ₹1.15 billion vs ₹1.10 billion)

What's Changed

• Q2 revenue increased to ₹1.15 billion from ₹1.10 billion in the corresponding prior-year period, demonstrating a growth of ≈4.55% YoY.

Key Takeaways

• Top-line expansion to ₹1.15 billion reflects stable commercial demand across scientific glassware and laboratory equipment segments.
• Year-on-year growth of ≈4.55% maintains positive momentum in operational revenue.
• Ongoing strategic investments in manufacturing capacity expansion provide operational tailwinds for future scale.

SAHI Perspective

Borosil Scientific continues to deliver consistent top-line performance, with Q2 revenue reaching ₹1.15 billion. The modest top-line increase underlines stable underlying demand in laboratory consumables while the company advances its planned production scale-up.

Market Implications

The positive revenue growth reinforces operational stability for Borosil Scientific. Market attention remains focused on execution of capital expenditure plans to convert expanded manufacturing capacity into higher future revenue streams.

Trading Signals

Market Bias: Bullish

Borosil Scientific posted Q2 revenue of ₹1.15 billion versus ₹1.10 billion YoY (≈4.55% growth). Operational scaling supported by ongoing manufacturing capex provides medium-term revenue stability.

Overweight: Laboratory Glassware & Equipment, Pharmaceutical Primary Packaging

Trigger Factors:

• Commercial progress on the ₹60 crore Bharuch manufacturing expansion target
• Quarterly margin trajectory and operating leverage expansion
• Sustained procurement demand from pharmaceutical R&D laboratories

Time Horizon: Medium-term (3-12 months)

Industry Context

Demand for specialized scientific glassware and laboratory instruments in India continues to be driven by pharmaceutical research, healthcare diagnostics, and academic research expansion.

Key Risks to Watch

• Fluctuations in raw material prices and energy costs involved in glass manufacturing
• Execution risks associated with commissioning additional manufacturing facilities
• Quarterly demand volatility from key pharmaceutical and educational laboratory clients

Recent Developments

On September 22, 2026, Borosil Scientific approved a ₹60 crore capital expenditure plan to set up an additional glassware manufacturing facility in Bharuch, Gujarat. The project is designed to expand production capacity from ~15 lakh units per annum to ~108 lakh units per annum, with commercial production targeted to start by March 2027.

Closing Insight

With stable Q2 revenue performance at ₹1.15 billion and active production expansion under execution, Borosil Scientific remains focused on scaling its core manufacturing capabilities for medium-term revenue enhancement.

High Performance Trading with SAHI.